Related Experiment Videos
Quality of life and patient preference for sequential versus continuous combined HRT: the UK Kliofem multicenter
L G Ulrich1, D H Barlow, D W Sturdee
1Department of Obstetrics and Gynaecology, Central Hospital of Nykøbing F, Denmark.
Insights
Continuous combined hormone replacement therapy (HRT) with Kliogest effectively relieved menopausal symptoms. Patient preference for Kliogest suggests improved compliance for long-term HRT benefits.
Area of Science:
- Menopause Management
- Pharmacology
- Women's Health
Background:
- Long-term hormone replacement therapy (HRT) is crucial for osteoporosis and cardiovascular disease prevention.
- Poor compliance with HRT limits its long-term benefits.
- Continuous combined HRT offers a potential solution for sustained treatment.
Purpose of the Study:
- To evaluate the effectiveness of continuous combined HRT (Kliogest) in relieving menopausal symptoms.
- To assess patient preference for Kliogest compared to previous sequential HRT regimens.
- To explore the potential of improved quality of life and patient preference in encouraging long-term HRT compliance.
Main Methods:
- A 9-month study involving 2151 postmenopausal women in the UK.
- Participants received daily Kliogest.
- Quality of life was measured using the Greene Climacteric Scale; patient preference questionnaires were completed.
Main Results:
- Continuous combined therapy with Kliogest was as effective as sequential therapy in alleviating menopausal symptoms.
- 91% of women preferred Kliogest over their previous sequential therapy.
- Improved quality of life was reported.
Conclusions:
- Continuous combined HRT with Kliogest is effective for menopausal symptom relief.
- High patient preference for Kliogest may enhance long-term treatment compliance.
- Increased compliance can lead to greater realization of HRT's benefits for bone and cardiovascular health.
Abstract:
Hormone replacement therapy (HRT) must be taken for many years to attain the long-term benefits on osteoporosis and cardiovascular disease. However, this level of compliance with HRT is rarely achieved. This analysis documents the effect of continuous combined HRT with Kliogest on the relief of menopausal symptoms, and the patient preference for HRT over a 9-month treatment period. A total of 2151 postmenopausal women, of whom 1435 were currently on sequential therapy and 716 had not been previously treated, were enrolled from 55 centers in the UK. Women received a daily tablet of Kliogest for 9 months. Quality of life was assessed using the Greene Climacteric Scale, and the women completed patient preference questionnaires. Treatment with continuous combined therapy was at least as effective as previous sequential regimens in alleviating menopausal symptoms. By the study conclusion, patient preference was strongly in favor of Kliogest with 91% of completers preferring it to their previous sequential therapy. Improved quality of life and patient preference for continuous combined therapy may encourage long-term compliance with treatment, allowing more women to experience the long-term beneficial effects of HRT on osteoporosis and cardiovascular disease.